paridiprubart   Click here for help

GtoPdb Ligand ID: 13714

Synonyms: EB05 | NI 0101 | NI-0101
Immunopharmacology Ligand
Compound class: Antibody
Comment: Paridiprubart (NI-0101; EB05) is a fully human monoclonal antibody that targets toll-like receptor 4 (TLR4) [2]. TLR4-induced signalling is a major contributor to pathological inflammatory responses. Paridiprubart blocks TLR4 signalling by preventing receptor dimerisation, thus disrupting receptor activation by any TLR4 ligand.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
A phase 2/3 trial of paridiprubart in patients with COVID-19-related ARDS was suspended by the developer for business reasons. It is also one of multiple therapeutic options to be evaluated for efficacy in hospitalized ARDS patients (NCT06703073). Paridiprubart was not efficacious in patients with rheumatoid arthritis (phase 2 trial) [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 Phase 2/Phase 3 Interventional Edesa Biotech Inc.
NCT06703073 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Phase 2 Interventional PPD DEVELOPMENT, LP